---
title: "Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286268941.md"
description: "Lake Street's Frank Takkinen has maintained a Buy rating on Stereotaxis (STXS) with a price target of $4.00. The analyst focuses on the Healthcare sector and has an average return of -1.2% with a 37.92% success rate on recommendations. The consensus on Stereotaxis is a Strong Buy, with an average price target of $4.13."
datetime: "2026-05-13T13:17:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286268941.md)
  - [en](https://longbridge.com/en/news/286268941.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286268941.md)
generator: "portal-rs"
---

# Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Stereotaxis, with a price target of $4.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Takkinen covers the Healthcare sector, focusing on stocks such as Stereotaxis, LENSAR, and TriSalus Life Sciences. According to TipRanks, Takkinen has an average return of -1.2% and a 37.92% success rate on recommended stocks. 

Currently, the analyst consensus on Stereotaxis is a Strong Buy with an average price target of $4.13.

### Related Stocks

- [STXS.US](https://longbridge.com/en/quote/STXS.US.md)
- [LNSR.US](https://longbridge.com/en/quote/LNSR.US.md)
- [TLSI.US](https://longbridge.com/en/quote/TLSI.US.md)
- [TLSIW.US](https://longbridge.com/en/quote/TLSIW.US.md)

## Related News & Research

- [Morgans Remains a Buy on EchoIQ Limited (EIQ)](https://longbridge.com/en/news/297720502.md)
- [09:01 ETHealthcare Is Moving Into the Home. Home Accessibility Now Has a Validated Score.](https://longbridge.com/en/news/297656740.md)
- [SoundHound AI (SOUN) On Healthcare Deal Momentum And The Case For A Higher Valuation](https://longbridge.com/en/news/297694466.md)
- [RBC Capital Keeps Their Buy Rating on Cytokinetics (CYTK)](https://longbridge.com/en/news/297724700.md)
- [Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital](https://longbridge.com/en/news/297470988.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**